Pelthos Therapeutics Inc. (PTHS) - Net Assets
Based on the latest financial reports, Pelthos Therapeutics Inc. (PTHS) has net assets worth $38.88 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($130.40 Million) and total liabilities ($91.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Pelthos Therapeutics Inc. (PTHS) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $38.88 Million |
| % of Total Assets | 29.82% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Pelthos Therapeutics Inc. - Net Assets Trend (2021–2025)
This chart illustrates how Pelthos Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore Pelthos Therapeutics Inc. balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Pelthos Therapeutics Inc. (2021–2025)
The table below shows the annual net assets of Pelthos Therapeutics Inc. from 2021 to 2025. For live valuation and market cap data, see how much is Pelthos Therapeutics Inc. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $38.88 Million | +1532.58% |
| 2024-12-31 | $-2.71 Million | +57.89% |
| 2023-12-31 | $-6.44 Million | -73.87% |
| 2022-12-31 | $-3.71 Million | -0.71% |
| 2021-12-31 | $-3.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pelthos Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6111373300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $103.67 Million | 266.65% |
| Total Equity | $38.88 Million | 100.00% |
Pelthos Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Pelthos Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Nanshan Power Co Ltd
SHE:200037
|
$85.55 Million |
|
Vissem Electronics Co. Ltd
KQ:072950
|
$85.56 Million |
|
Marks and Spencer Group PLC
LSE:MKS
|
$85.57 Million |
|
Ecos India Mobility & Hospitality Ltd
NSE:ECOSMOBLTY
|
$85.57 Million |
|
Indorama Synthetics Tbk
JK:INDR
|
$85.50 Million |
|
Fortune Mate Indonesia Tbk
JK:FMII
|
$85.50 Million |
|
Dae Chang
KO:012800
|
$85.49 Million |
|
Actinogen Medical Ltd
AU:ACW
|
$85.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pelthos Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,714,054 to 38,881,000, a change of 41,595,054.
- Net loss of 43,319,000 reduced equity.
- Other factors increased equity by 84,914,054.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-43.32 Million | -111.41% |
| Other Changes | $84.91 Million | +218.39% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Pelthos Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-6.38 | $26.66 | x |
| 2022-12-31 | $-6.43 | $26.66 | x |
| 2023-12-31 | $-11.17 | $26.66 | x |
| 2024-12-31 | $-4.62 | $26.66 | x |
| 2025-12-31 | $20.68 | $26.66 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pelthos Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -111.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -257.93%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 3.35x
- Recent ROE (-111.41%) is below the historical average (-22.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-227.36K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.09 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.74 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.68 Million |
| 2025 | -111.41% | -257.93% | 0.13x | 3.35x | $-47.21 Million |
Industry Comparison
This section compares Pelthos Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,624,003
- Average return on equity (ROE) among peers: -53.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | $38.88 Million | 0.00% | 2.35x | $85.55 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $98.85 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.59 Billion |
| Abeona Therapeutics Inc (ABEO) | $67.72 Million | -21.45% | 0.18x | $309.44 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $181.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $795.12 Million |
| Arbutus Biopharma Corp (ABUS) | $30.03 Million | -30.65% | 0.08x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $18.59 Million | -164.77% | 1.78x | $9.67 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $479.08 Million | -51.18% | 0.13x | $3.61 Billion |
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus… Read more